844-MY NK CELLScontact@nantkwest.com

      INVESTOR RELATIONS

      Overview

      We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put NantKwest, Inc.'s financial performance into perspective.
      NK (Common Stock) $3.620.00 (0.00%)
      Data provided by Nasdaq. Minimum 15 minutes delayed.

      Latest News

      NantKwest Announces FDA Grant of Orphan Drug Designation for the Company’s aNK Natural Killer Cell Therapy in Merkel Cell Carcinoma

      Mar 20, 2017 | Press Releases

      CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 20, 2017-- NantKwest, Inc. (Nasdaq:N

      Read More

      NantKwest to Present at Upcoming Investor Conferences

      Mar 06, 2017 | Press Releases

      CULVER CITY, Calif.--(BUSINESS WIRE)--Mar. 6, 2017-- NantKwest (Nasdaq:NK) toda

      Read More

      Landmark First-In-Human Clinical Study Launch Using a Genetically Engineered Natural Killer Cell for the Treatment of Cancer

      Jan 23, 2017 | Press Releases

      CULVER CITY, Calif.--(BUSINESS WIRE)--Jan. 23, 2017-- NantKwest Inc. (Nasdaq:NK

      Read More

      Receive E-mail Alerts
      Sign up to receive e-mail alerts whenever Nantkwest Inc posts new information to the site. Just enter your e-mail address and click Submit.